| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
Preparation Method | Transdermal Peptide (TD 1 (peptide)) or ATP1B1 were incubated in 96-well plates with 0.05 M NaHCO 3 for 12 h at 4 ℃. Cell lysates were incubated with fixed Transdermal Peptide (TD 1 (peptide)) for 2 h at 37℃. |
Reaction Conditions | 0.5 mg/mL Transdermal Peptide (TD 1 (peptide)) for 2 h at 37℃. |
Applications | The interaction between Transdermal Peptide (TD 1 (peptide)) (0.5 mg/mL) and the full-length ATP1B1 or the C-terminus of ATP1B1 was dose-dependent. |
Cell lines | HaCaT cells |
Preparation Method | HaCaT cells were treated with Transdermal Peptide (TD 1 (peptide)) to study the expression of ATP1B1. |
Reaction Conditions | 20 μg/mL Transdermal Peptide (TD 1 (peptide)) |
Applications | Transdermal Peptide (TD 1 (peptide)) affects the localization of ATP1B1 in HaCaT cells, ATP1B1 is initially uniformly distributed in cells, whereas after treatment with Transdermal Peptide (TD 1 (peptide)), it accumulates near the cell membrane. |
Animal models | Adult male SD rats (200 ± 10 g) |
Preparation Method | For in vivo skin permeation, 50 μg of Transdermal Peptide (TD 1 (peptide))-hEGF was coadministered with 500 μg of ouabain, 50 μg of GST-ATP1B1, or 50 μg of GST (control group) on the abdomen of rats for 6 h. |
Dosage form | 50 μg Transdermal Peptide (TD 1 (peptide)) for 6h(i.p). |
Applications | When ouabain was coadministered, the transdermal delivery of Transdermal Peptide (TD 1 (peptide))-hEGF, a fusion protein composed of Transdermal Peptide (TD 1 (peptide)) and hEGF, was significantly reduced. The addition of the exogenous competitor can also cause a decrease in the transdermal delivery of Transdermal Peptide (TD 1 (peptide))-hEGF. Therefore, ATP1B1 played a key role in the peptide-directed drug delivery across the skin. |
| 产品描述 | Transdermal Peptide (TD 1 (peptide)), consisting of 11 amino acids, is the first transdermal enhancing peptide discovered by phage display. Transdermal Peptide binds to Na+/K+-ATPase beta-subunit (ATP1B1), and enhances the transdermal delivery of many macromolecules[1,2]. Transdermal Peptide (TD 1 (peptide))1 has been found to facilitate the transdermal delivery of many macromolecules such as botulinum neurotoxin type A (BoNT-A), growth hormone (GH), siRNA and human epidermal growth factor (hEGF) [3,4]. Energy is required for the Transdermal Peptide (TD 1 (peptide))-mediated transdermal protein delivery through rat and human skins.A novel energy-dependent permeation process during the Transdermal Peptide (TD 1 (peptide))-mediated transdermal protein delivery[7]. When ouabain was coadministered, the transdermal delivery of Transdermal Peptide (TD 1 (peptide))-hEGF, a fusion protein composed of Transdermal Peptide (TD 1 (peptide)) and hEGF, was significantly reduced. The addition of the exogenous competitor can also cause a decrease in the transdermal delivery of Transdermal Peptide (TD 1 (peptide))-hEGF. Therefore, ATP1B1 played a key role in the peptide-directed drug delivery across the skin[1]. Coadministration of Transdermal Peptide (TD 1 (peptide)) and insulin to the abdominal skin of diabetic rats resulted in elevated systemic levels of insulin and suppressed serum glucose levels for at least 11 h. Significant systemic bioavailability of human growth hormone was also achieved when topically coadministered with Transdermal Peptide (TD 1 (peptide))[2]. Blood glucose level lowered to about 26% of initial after administrating 2.1 IU insulin with 0.5 µmol of TD-34 in 100 µL of saline for 8 h to diabetic rats in vivo[6]. Transdermal Peptide (TD 1 (peptide)) delivery of anti-GAPDH siRNA significantly reduced the level of GAPDH in 72 h. Transdermal Peptide (TD 1 (peptide)) can create a transient opening in non-follicle rat skin for delivery of siRNA and reveal a novel mechanism of transdermal delivery of Transdermal Peptide (TD 1 (peptide)) and siRNA into the epidermis for gene knockdown[5]. References: |
m.cnreagent.com